Page 42 - GPD-1-1

Gene & Protein in Disease Genetically engineered T cells in cancer immunotherapy

management. Blood Rev, 34: 45–55. 41. Huarte E, O’Connor RS, Peel MT, et al., 2020, Itacitinib
(INCB039110), a JAK1 inhibitor, reduces cytokines
https://doi.org/10.1016/j.blre.2018.11.002
associated with cytokine release syndrome induced by CAR
31. Maude SL, Frey N, Shaw PA, et al., 2014, Chimeric antigen T-cell therapy. Clin Cancer Res, 26(23): 6299–6309.
receptor T cells for sustained remissions in leukemia. N Engl
J Med, 371(16): 1507–1517. https://doi.org/10.1158 / 1078-0432.CCR-20-1739
https://doi.org/10.1056/NEJMoa1407222 42. Casucci M, Falcone L, Camisa B, et al., 2018, Extracellular
NGFR spacers allow efficient tracking and enrichment of
32. Gust J, Hay KA, Hanafi LA, et al., 2017, Endothelial activation fully functional CAR-T cells co-expressing a suicide gene.
and blood-brain barrier disruption in neurotoxicity after Front Immunol, 9: 507.
adoptive immunotherapy with CD19 CAR-T cells. Cancer
Discov, 7(12): 1404–1419. https://doi.org/10.3389/fimmu.2018.00507
https://doi.org/10.1158 / 2159-8290.CD-17-0698 43. Ying Z, Huang XF, Xiang X, et al., 2019, A safe and potent
anti-CD19 CAR T cell therapy. Nat Med, 25(6): 947–953.
33. Giavridis T, van der Stegen SJ, Eyquem J, et al., 2018, CAR
T cell-induced cytokine release syndrome is mediated by https://doi.org/10.1038/s41591-019-0421-7
macrophages and abated by IL-1 blockade. Nat Med, 24(6): 44. Brudno JN, Lam N, Vanasse D, et al., 2020, Safety and
731–738. feasibility of anti-CD19 CAR T cells with fully human
https://doi.org/10.1038/s41591-018-0041-7 binding domains in patients with B-cell lymphoma. Nat
Med, 26(2): 270–280.
34. Fischer JW, Bhattarai N, 2021, CAR-T cell therapy:
Mechanism, management, and mitigation of inflammatory https://doi.org/10.1038/s41591-019-0737-3
toxicities. Front Immunol, 12: 693016. 45. Fraietta JA, Lacey SF, Orlando EJ, et al., 2018, Determinants
https://doi.org/10.3389/fimmu.2021.693016 of response and resistance to CD19 chimeric antigen
receptor (CAR) T cell therapy of chronic lymphocytic
35. Chen X, Li X, Liu Y, et al., 2020, A phase I clinical trial of leukemia. Nat Med, 24(5): 563–571.
chimeric antigen receptor-modified T cells in patients with
relapsed and refractory lymphoma. Immunotherapy, 12(10): https://doi.org/10.1038/s41591-018-0010-1
681–696.
46. Deng Q, Han G, Puebla-Osorio N, et al., 2020, Characteristics
https://doi.org/10.2217/imt-2020-0022 of anti-CD19 CAR T cell infusion products associated with
efficacy and toxicity in patients with large B cell lymphomas.
36. Norelli M, Camisa B, Barbiera G, et al., 2018, Monocyte-
derived IL-1 and IL-6 are differentially required for Nat Med, 26(12): 1878–1887.
cytokine-release syndrome and neurotoxicity due to CAR T https://doi.org/10.1038/s41591-020-1061-7
cells. Nat Med, 24(6): 739–748.
47. Wang X, Brea LT, Yu J, 2019, Immune modulatory functions
https://doi.org/10.1038/s41591-018-0036-4 of EZH2 in the tumor microenvironment: Implications in
37. Staedtke V, Bai RY, Kim K, et al., 2018, Disruption of a self- cancer immunotherapy. Am J Clin Exp Urol, 7(2): 85–91.
amplifying catecholamine loop reduces cytokine release 48. John LB, Devaud C, Duong CP, et al., 2013, Anti-PD-1
syndrome. Nature, 564(7735): 273–277. antibody therapy potently enhances the eradication of
https://doi.org/10.1038/s41586-018-0774-y established tumors by gene-modified T cells. Clin Cancer
Res, 19(20): 5636–5646.
38. Liu Y, Fang Y, Chen X, et al., 2020, Gasdermin E-mediated
target cell pyroptosis by CAR T cells triggers cytokine release https://doi.org/10.1158 / 1078-0432.CCR-13-0458
syndrome. Sci Immunol, 5(43): eaax7969. 49. Choi BD, Yu X, Castano AP, et al., 2019, CRISPR-Cas9
https://doi.org/10.1126/sciimmunol.aax7969 disruption of PD-1 enhances activity of universal EGFRvIII
CAR T cells in a preclinical model of human glioblastoma.
39. Liu Y, Chen X, Wang D, et al., 2018, Hemofiltration J Immunother Cancer, 7(1): 304.
successfully eliminates severe cytokine release syndrome
following CD19 CAR-T-cell therapy. J Immunother, 41(9): https://doi.org/10.1186/s40425-019-0806-7
406–410. 50. Chong EA, Alanio C, Svoboda J, et al., 2022,
https://doi.org/10.1097/CJI.0000000000000243 Pembrolizumab for B-cell lymphomas relapsing after or
refractory to CD19-directed CAR T-cell therapy. Blood,
40. Xiao X, He X, Li Q, et al., 2019, Plasma exchange can be an 139(7): 1026–1038.
alternative therapeutic modality for severe cytokine release
syndrome after chimeric antigen receptor-T cell infusion: https://doi.org/10.1182/blood.2021012634
A case report. Clin Cancer Res, 25(1): 29–34.
51. Liu M, Wang X, Li Z, et al., 2020, Synergistic effect of
https://doi.org/10.1158 / 1078-0432.CCR-18-1379 ibrutinib and CD19 CAR-T cells on Raji cells in vivo and

Volume 1 Issue 1 (2022) 11 https://doi.org/10.36922/gpd.v1i1.114